AMETEK INC（AME）の決算・業績分析
AMETEK INCの2025年有価証券報告書をAI分析。売上高$7.4B(+6.6%)。営業利益$1.9B。Health Care。
目次
AMETEK INCの2025年度 業績サマリー
AMETEK INC（証券コード: AME）の2025年度決算・業績分析。売上高は$7.4B（前年比+6.6%）。営業利益は$1.9B（前年比+7.3%）。純利益は$1.5B（前年比+7.6%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
AMETEK INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 10.9% YoY to $6.2B (XBRL), driven by acquisitions and strong international demand.
- Operating income surged 14.7% YoY to $1.5B (XBRL), with EMG segment revenue rising 15.6% to $2.28B (10-K).
- Net income increased 17.1% YoY to $1.2B (XBRL), supported by Operational Excellence initiatives and strong EBITDA margins (29.6%).
- Free cash flow reached $1.0B (XBRL), with $333M allocated to share repurchases and $202M in dividends (XBRL).
- Net debt stood at $1.5B (0.8x EBITDA) (XBRL), reflecting disciplined capital structure management.
AMETEK INCの売上高変化の要因
- •Total revenue reached $6.2B (XBRL), up 10.9% YoY. The EMG segment led growth with a 15.6% increase to $2.28B (10-K), while EIG revenue rose 0.8% to $4.66B (10-K). Growth was fueled by acquisitions (7% contribution) and strong demand in Europe/Asia, partially offset by a 2% organic sales decline. The Virtek Vision International acquisition ($117.5M) (10-K) added to EMG's expansion.
AMETEK INCの営業利益変化の要因
- •Operating margin expanded to 24.4% (XBRL), up from prior years, with EBITDA at $1.8B (29.6% margin). Net margin reached 18.9% (XBRL), reflecting improved cost management and Operational Excellence initiatives. Gross profit data is not available in XBRL, but operating income grew 14.7% YoY to $1.5B (XBRL).
AMETEK INCの事業リスクと対応
Cyclical downturns in aerospace, defense, and energy markets could reduce demand (10-K).
Failure to execute Operational Excellence initiatives may harm cost savings and efficiency (10-K).
International operations face trade barriers, currency fluctuations, and geopolitical risks (10-K).
Compliance with export laws and economic sanctions could disrupt transactions (10-K).
Foreign exchange rate volatility may impact international sales and financial reporting (10-K).
AMETEK INCの今後の見通し・業績予想
AMETEK INCの事業内容
AMETEK Inc. (AME) is a global manufacturer of electronic instruments and electromechanical devices, serving aerospace, medical, and industrial automation markets through two segments: Electronic Instruments (EIG) and Electromechanical (EMG). The company differentiates itself via niche market leadership, advanced manufacturing capabilities, and a focus on high-quality, differentiated products. Key competitive advantages include significant market share in specialized segments, robust R&D ($199M in FY2024) (XBRL), and a long-tenured management team (10-K). Customer concentration is not explicitly detailed in the 10-K, but demand is driven by capital spending in aerospace, defense, and industrial sectors.
AMETEK INCのAI業績分析レポート（2024年度）
AMETEK Inc. (AME) Annual Report Analysis FY2024
Highlights
Business Overview
AMETEK Inc. operates through two segments: Electronic Instruments (EIG) and Electromechanical (EMG). The company serves aerospace, medical, and industrial automation markets with differentiated products and global manufacturing capabilities. Competitive advantages include niche market leadership, R&D investment ($199M) (XBRL), and experienced management (10-K). No significant customer concentration is disclosed (10-K).
Revenue Analysis
Total revenue reached $6.2B (XBRL), up 10.9% YoY. EMG revenue grew 15.6% to $2.28B (10-K), driven by the Virtek acquisition ($117.5M) (10-K). EIG revenue increased 0.8% to $4.66B (10-K), offset by a 2% organic decline. Acquisitions contributed 7% to revenue growth.
Profitability Analysis
Operating margin expanded to 24.4% (XBRL), with EBITDA at $1.8B (29.6% margin). Net income rose 17.1% YoY to $1.2B (XBRL). Gross profit data is not available in XBRL, but operating income growth reflects strong demand in Europe/Asia (10-K).
Balance Sheet Analysis
Equity ratio: 60.1% (XBRL). Total equity: $7.5B (XBRL). Long-term debt: $1.9B (XBRL). Net debt: $1.5B (0.8x EBITDA). Cash reserves: $410M (XBRL). Current ratio: 0.98x (XBRL).
Cash Flow Analysis
Operating cash flow: $1.1B (XBRL). Free cash flow: $1.0B (XBRL). CapEx: $139M (XBRL). Shareholder returns: $535M (XBRL) ($202M dividends + $333M buybacks).
Working Capital Analysis
N/A (data not available in XBRL or 10-K).
Risks
Outlook
Management expects continued strength in international demand and the impact of recent acquisitions (10-K). No explicit guidance was provided for FY2025.
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 4.8B | 5.2B | 4.5B | 5.5B | 6.2B | 6.6B |
| Operating Income | 1.1B | 1.2B | 1.0B | 1.3B | 1.5B | 1.7B |
| Net Income | 778M | 861M | 872M | 990M | 1.2B | 1.3B |
| Total Assets | 9.8B | 10.4B | 11.9B | 12.4B | 12.4B | 15.0B |
| Total Equity | 4.2B | 5.1B | 5.9B | 6.9B | 7.5B | 8.7B |
| Operating Cash Flow | 926M | 1.1B | 1.3B | 1.2B | 1.1B | 1.7B |
Health Careの企業一覧
AMETEK INCと同じ「Health Care」セクターの企業